Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Full Story
3,008,000 news articles indexed and analysed from 346 sources in 4 languages.
Articles and images are sorted, ranked and categorised automatically, placement is not intended to cause offence.
WireBeat accepts no liability for the content published by third parties.
English ¦ 
Spanish ¦ 
French ¦ 
German
© Accumudata Limited 2022 Release Version 1.22 Company Number: 12846061 All Rights Reserved.